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Special Report
Introduction of Biosimilar Therapeutics Into Nephrology Practice
in the United States: Report of a Scientific Workshop Sponsored
by the National Kidney Foundation
Jay B. Wish, MD,1 Chaim Charytan, MD,2 Glenn M. Chertow, MD,3
Kamyar Kalantar-Zadeh, MD,4 Alan S. Kliger, MD,5 Robert J. Rubin, MD,6
Jerry Yee, MD,7 and Steven Fishbane, MD 8
Biosimilars are biologic medicines highly similar to the reference product with no meaningful clinical differences in terms of safety, purity, and potency. All biologic medicines are produced by living cells, resulting in
an inherent heterogeneity in their higher order structures and post-translational modifications. In 2010, the US
Congress enacted legislation to streamline the approval process for biosimilars of products losing patent
protection, with the goal of decreasing costs and improving patient access to therapeutically important but
expensive biologic agents. In 2015, the US Food and Drug Administration approved the first biosimilar agent
through this pathway. Approval of additional biosimilar agents in the United States, including those used by
nephrologists, is anticipated. Given the relative lack of knowledge regarding biosimilars and their approval
process and a lack of trust by the nephrology community regarding their safety and efficacy, the National
Kidney Foundation conducted a symposium, Introduction of Biosimilar Therapeutics Into Nephrology Practice
in the U.S., September 17 to 18, 2015. Issues related to manufacturing, the regulatory approval process,
interchangeability, substitution/switching, nomenclature, and clinician and patient awareness and acceptance
were examined. This report summarizes the main discussions at the symposium, highlights several controversies, and makes recommendations related to public policy, professional and patient education, and
research needs.
Am J Kidney Dis. 68(6):843-852. ª 2016 by the National Kidney Foundation, Inc.
INDEX WORDS: Biosimilar; biologic; erythropoietin analogue; dialysis; regulatory; therapeutic equivalency;
reference agent; drug approval; safety; efficacy; cost; anemia; nephrology; end-stage renal disease
(ESRD); pharmacovigilance; interchangeability.

B

iologic products have been available for several
decades as important therapeutic options for a
number of serious conditions.1 Biologics are substances produced by living cells using biotechnology
(ie, recombinant DNA technology, controlled gene
expression, or antibody technologies) and include a
wide range of substances, such as recombinant hormones, growth factors, blood products, monoclonal
antibody–based products, recombinant vaccines, and
advanced technology products (eg, gene and cell
therapy biological products).1 Because biologics are
produced by living cells, as opposed to chemical reactions that produce small-molecule drugs, biologics
have an inherent heterogeneity in their higher order
structures and post-translational modiﬁcations.
Biosimilars, as described by the US Food and Drug
Administration (FDA), are biological medicines (biologics) that are “highly similar to the US-licensed
biological product [also referred to as “reference” or
“originator” product] notwithstanding minor differences in clinically inactive components.there are no
clinically meaningful differences between the biologic product and the reference product in terms of the
safety, purity, and potency of the product.”2 It may be
interesting to note that due to clinically insigniﬁcant structural heterogeneity secondary to multiple

manufacturing changes over time,3 many current
reference biologics can be likened to “biosimilars” of
the originally licensed product, although they are not
designated so by the FDA.
Although the ﬁrst biosimilar was approved and
marketed in Europe in 2006, an abbreviated licensure
pathway for biosimilars in the United States was
enacted in 2010 as part of the Patient Protection and
Affordable Care Act. It is anticipated that the availability of FDA-approved biosimilars in the United
States will allow for reduced cost of and increased

From 1Indiana University Health, Indianapolis, IN; 2New York
Presbyterian-Queens, Queens, NY; 3Stanford University, Stanford,
CA; 4University of California-Irvine, Orange, CA; 5Yale New
Haven Health System, New Haven, CT; 6Georgetown University,
Washington, DC; 7Henry Ford Hospital, Detroit, MI; and 8Hofstra Northwell School of Medicine, Great Neck, NY.
Received January 26, 2016. Accepted in revised form June 7,
2016. Originally published online September 3, 2016.
Address correspondence to Jay B. Wish, MD, Division of
Nephrology, IU Health University Hospital, 550 N University
Blvd, Ste 6100, Indianapolis, IN 46202. E-mail: jaywish@
earthlink.net
 2016 by the National Kidney Foundation, Inc.
0272-6386
http://dx.doi.org/10.1053/j.ajkd.2016.06.022

Am J Kidney Dis. 2016;68(6):843-852
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on June 15, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

843

Wish et al

patient access to biologics.4,5 Nine of the 10 highest
Medicare Part B expenditure drugs in 2014 were biologics, accounting for more than $9 billion in
Medicare Part B spending.6 There is growing
awareness of the potential for impending biosimilar
development and approval as drugs in several therapeutic categories are known to have expiring patents.7
It is unclear what the full economic effect of biosimilars in the United States will be, but the
Congressional Budget Ofﬁce has estimated a reduction in cumulative total spending on biologics of $25
billion by 2018.8 More recently, the Rand Corporation estimated that biosimilars could result in a
reduction of $44.2 billion in spending (4% of all
spending on biologics) between 2014 and 2024.9
Although some products considered biosimilar in
other regulatory environments gained FDA approval
before the new pathway was created, only 2 agents
(ﬁlgrastim and inﬂiximab) deemed to be a biosimilar
according to the current regulatory pathway were
approved by the FDA as of April 2016.10 Guidance
from the FDA on biosimilars has been slow to emerge
due to debates by stakeholders over how stringent the
standards for new biosimilar approvals should be and
whether approved biosimilars should be used interchangeably with reference products going forward.11,12 In 2015, the FDA released ﬁnal guidance
for industry on scientiﬁc13 and quality14 considerations and a draft guidance on nonproprietary naming
of biologic products that also addressed interchangeability.15 Interchangeability refers to the ability of a
pharmacist to substitute a biosimilar product for the
reference product without intervention by the physician or advanced practice provider who prescribed the
reference biologic product. The designation of
“interchangeable” requires higher standards than
“biosimilarity” alone and the sponsor must demonstrate that “if the biologic product is administered
more than once to an individual, the risk in terms of
safety or diminished efﬁcacy of alternating or
switching between the use of the biologic product and
the reference product is not greater than using the
reference product without such alteration or
switch.”15 The FDA has solicited input from stakeholders to guide its development of the ﬁnal rule on
these issues. A timeline of FDA guidance for the
regulatory approval of biosimilars is shown in
Table 1.
Clinicians remain concerned about the safety, efﬁcacy, and appropriate use of biosimilars. A 2013
survey of multiple clinical disciplines found there was
a low level of understanding of the differences between biosimilars and generics, as well as the differences between biosimilars and reference biologics
(.66% rated their understanding as “fair” or “poor”).
Nearly 100% of respondents indicated a high level of
844

Table 1. Timeline of FDA Guidance for the Regulatory Approval
of Biosimilars
Timing

Action

March 2010

February 2012

March 2013
May 2014
September 2014
March 2015
April 2015

May 2015

March 2016

Biologics Price Competition and Innovation
Act passed as part of the Affordable
Care Act
Draft guidance on biosimilars: scientific
considerations, quality considerations,
questions and answers
Draft guidance on formal meetings with
FDA and sponsors
Draft guidance on biosimilars: clinical
pharmacology data
FDA announces “Purple Book” (lists of
licensed biologic products)
First biosimilar approved
Final guidance on biosimilars: scientific
considerations, quality considerations,
questions and answers
Draft guidance on biosimilars: naming and
interchangeability, additional questions
and answers
Draft guidance on labeling of biosimilar
products

Abbreviation: FDA, US Food and Drug Administration.

need for continuing education on biosimilars.16 The
oncology community published a position paper
regarding regulatory and clinical considerations for
biosimilar oncology drugs in 2014,17 many themes of
which are reﬂected in this report.

BIOSIMILARS IN NEPHROLOGY
Optimizing the safety and efﬁcacy of the treatment
of anemia is one of the key challenges in chronic
kidney disease (CKD) management.18 Anemia is
increasingly prevalent as CKD progresses, affecting
nearly 80% of patients with CKD stage 5.19 The many
facets of anemia management in patients with CKD
are superimposed against a climate of recent changes
in anemia treatment. In Europe, several epoetin biosimilars have received marketing authorization, and
data to date show that all these agents, considered by
the European Medicines Agency to be therapeutically
equivalent to the reference drugs,20 have safety proﬁles that are also similar to the reference drugs.21 In
the United States, all FDA-approved erythropoiesisstimulating agents (ESAs) were erythropoietin analogues until 2012, when a synthetic pegylated peptide
with no structural similarity to recombinant human
erythropoietin (peginesatide [Omontys, Affymax])
was approved for use in patients undergoing dialysis.
However, this drug is no longer available in the
United States because of a voluntary manufacturer
recall due to postmarketing reports of fatal anaphylactic reactions.22,23 It should be noted that the
adverse reactions to peginesatide were not due to
Am J Kidney Dis. 2016;68(6):843-852
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immunogenicity, which is one of the major safety
concerns regarding biosimilar agents. Nonetheless,
the change in ESA formulation with peginesatide
raised concerns among nephrologists regarding the
potential for toxicity. At least 2 biosimilar erythropoietin analogues are in a later-stage approval
pathway in the United States.24,25
To date, literature on biosimilars has arisen primarily from European sources because of agents that
are available to clinicians in these countries. Although
the position paper summarized in Box 1 speciﬁes the
need for informing European hematologists regarding
biosimilars, it is clear that nephrologists in the United
States are a key clinician group in need of education
because of their regular use of biologics. Education on
basic information to provide a context for biologics
and nephrologist-speciﬁc information that applies to
speciﬁc conditions, such as anemia, is a crucial step in
ensuring informed and optimal care of patients with
kidney disease.
One of the major concerns regarding biologics and
biosimilars is immunogenicity. Because these products are all proteins, they have the potential of being
recognized as foreign by the body and inducing an
immune response. The immune response may manifest as the production of neutralizing antibodies that
could decrease the efﬁcacy of the therapeutic agent; as
anaphylaxis or an immune complex disease with
manifestations of serum sickness such as fever,
arthritis, and vasculitis; or the cross-reacting of the
antibody with the native hormone, leading to signiﬁcant morbidity. In the case of ESAs, the development
of antibodies that cross-react with native erythropoietin can lead to pure red cell aplasia (PRCA), a severe
form of anemia due to the selective absence of red
blood cell production by the bone marrow. The

Box 1. Recommendations From Italian Hematology Societies
Regarding Biosimilars










To introduce biosimilars onto the market, transparent
impartial information must be provided to prescribers and
other health care providers
Physicians in the subspecialty must be educated about
the fundamental concepts and key issues related to
biosimilars
Because decisions concerning prescribing and substitutability are complicated and given that opinions are unlikely
to be unanimous and can be expected to be vulnerable to
conflicts of interest, professional societies should make it
a priority to make appropriate information available
To assist clinicians in making informed prescribing choices
related to biosimilars, professional societies should organize scientific meetings and produce guidelines
To help health care professionals make appropriate clinical decisions, scientific societies should have the goal of
ensuring access to all data pertaining to biosimilars

Based on Barosi et al.46

epidemiology of PRCA is an excellent lesson
regarding how fragile the process for the production,
packaging, and distribution of biologic products can
be. The ﬁrst collection of PRCA cases occurred in
Europe when the stabilizing agent in a reference ESA
interacted with the rubber in the plunger of preﬁlled
syringes.26 Two cases of PRCA occurred when a
biosimilar ESA in Europe interacted with the tungsten
used to manufacture preﬁlled syringes.27 Both these
episodes occurred in the highly regulated European
market, where the approval process for new medications is rigorous and systems for postapproval pharmacovigilance are well developed. In the ﬁrst
collection, the incidence of PRCA radically decreased
with a manufacturing change and with a shift from
subcutaneous to intravenous (IV) administration of
the ESA.28 In less well-regulated markets such as
Thailand, PRCA occurred at a rate of 1 in 2,068 patients at risk due to the use of ESAs developed with
poor oversight of manufacturing, packaging, and
distribution processes for biologics.29 These experiences have raised concerns among nephrologists
regarding the risk for PRCA from biosimilar ESAs. It
should be noted that none of the biosimilar ESAs
approved and in use in Europe since 2007 has been
associated with PRCA except for the small number of
cases attributed to the tungsten interaction.27 Due to
concerns primarily regarding PRCA, the United
Kingdom did not approve a biosimilar epoetin until
2014, which is 7 years after the rest of the European
Union did so.
To address these regulatory and clinical concerns,
the National Kidney Foundation (NKF) sponsored a
scientiﬁc workshop on Introduction of Biosimilar
Therapeutics Into Nephrology Practice in the U.S.,
held September 17 to 18, 2015, in New York. The
symposium’s objectives were to examine issues
related to manufacturing, the regulatory approval
process, interchangeability, substitution/switching,
nomenclature, and clinician and patient awareness
and acceptance. The meeting, attended by 43 experts,
was organized to allow an in-depth discussion on:
(1) public policy, (2) education, and (3) research opportunities. This report summarizes the main discussions at the meeting, highlights several controversies,
and makes recommendations related to the mentioned
areas.

PUBLIC POLICY WORK GROUP REPORT
The Biologics Price Competition and Innovation
(BPCI) Act of 2009 creates an abbreviated licensure
pathway for biologic products shown to be biosimilar
to or interchangeable with an FDA-licensed reference
product. The intent of the BPCI Act was to make
biologics more affordable by providing a clear
pathway to approval that facilitates the insight that the
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biosimilar product is similar to the reference product
with regard to chemical structure, efﬁcacy, safety,
potency, pharmacokinetics, and pharmacodynamics.
Approval can be granted by demonstrating “biosimilarity” of a new product to a previously approved
and licensed reference product that has been shown to
be safe and effective. The BPCI Act left open several
implementation issues to be left to the discretion of
the 2 responsible federal agencies: the FDA and the
Centers for Medicare & Medicaid Services (CMS).
The FDA has issued “guidance” on the approval
process for biosimilar drugs2,5,8-10 (Table 1), and the
CMS has addressed payment for biosimilars under
Medicare Part B in regulations published on
November 6, 2015.30
Five policy issues were discussed and recommendations of the group follow.
How Should Biosimilars Be Named?
In August 2015, the FDA issued draft guidance on
how they intended to name biosimilars.10 The goals of
the naming convention were to help minimize inadvertent substitution and to facilitate pharmacovigilance. The FDA also desired to avoid inaccurate
perceptions of the safety and effectiveness of biological products based on their licensure pathway. To
accomplish these goals, the FDA proposed a name
with 2 parts: a core name that would be the component shared among all related biological products, and
a sufﬁx that would be 4 lowercase letters that are
unique and “devoid of meaning.” There was broad
support for the core name, but there was discussion
regarding the alternate use of a company identiﬁer as
the sufﬁx. It was generally believed that inclusion of a
company identiﬁer as the sufﬁx might make it easier
for physicians and advanced practice providers to
know which biosimilar they were prescribing. However, the recommendation of the FDA, as well as the
need to rename should a company be acquired or
change its name, made a non–company-speciﬁc sufﬁx
devoid of meaning the preferred option. A secondary
nomenclature issue is whether interchangeable biosimilars should have the same sufﬁx as the innovator
drug. The work group strongly thought that doing that
would violate the second FDA goal of promoting
pharmacovigilance.
What Should Be the Policy of Individual States
Regarding Substitution/Switching of Interchangeable
Biosimilars?
Currently there is universal substitution for generic
pharmaceuticals unless a physician or licensed
nonphysician advanced practice provider writes
“Dispense as written” (DAW; or words to that effect).
When there are multiple suppliers of a generic drug,
each time a pharmacist ﬁlls a prescription, she or he
846

may do so with a generic produced by a different
manufacturer from the originator product. These decisions are made regularly without notiﬁcation of the
prescribing provider. Should interchangeable biosimilars be managed in the same manner? This policy
falls under state pharmacy dispensing laws. Nineteen
states and Puerto Rico have passed legislation to
permit automatic substitution of interchangeable biosimilars by the pharmacist. Virginia and Oregon have
provisions obligating physician (or provider)
communication, but these provisions expire in 2015
and 2016, respectively. As of 2016, whether providers
are informed is moot because there are no interchangeable biosimilars. Work group members
generally believed that physicians and advanced
practice providers should be notiﬁed in a timely
manner of the substitution and that prescribers should
continue to have the ability to prohibit substitution by
a DAW designation. There was concern by the work
group that although a product may be interchangeable
in its pharmacologic effect, the active ingredient may
be made using a different biological system and may
be associated with unintended effects that cause
concern. Individual patients might also have idiosyncratic reactions to the inactive components of a
biosimilar, precluding its use in their case. When a
product has an established safety record over at least 5
years, physicians and advanced practice providers
may not need to be regularly informed of switches. A
derivative issue is whether patients should be
informed of a substitution or switch. The work group
believes that any process of substitution or switching
should be fully transparent and therefore the patient
should be informed at the time of dispensing whether
he or she is receiving the reference product or an
interchangeable or biosimilar one. A similar level of
transparency should be provided by health insurance
plans, hospitals, infusion centers, and dialysis care
providers. As noted in the previous section, it should
always be possible to identify the speciﬁc biosimilar
dispensed in case the patient develops an unexpected
reaction to the agent.
How Should Biosimilars Be Coded for Payment and
Pharmacovigilance Purposes?
The CMS proposes that all biosimilars of a
particular reference biologic drug be given the same
billing code and the same payment. It is anticipated
that the payment would be derived from 100% of the
weighted average selling price of the biosimilar(s)
plus 6% of the average selling price of the reference
drug. The ﬁrst part of the proposal, that all biosimilars
related to a particular reference product have the same
Healthcare Common Procedure Coding System
(HCPCS), raised the concern that such a policy
would weaken pharmacovigilance. The work group
Am J Kidney Dis. 2016;68(6):843-852
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endorsed the principle that whatever coding system is
used by the CMS strengthen and not weaken pharmacovigilance. There are several alternative methodologies that would allow the CMS and private payers
to implement the CMS pricing policy and still use the
claims process to track individual biosimilars. An indepth analysis of these potential payment approaches
to allow optimal pharmacovigilance was beyond the
scope of the symposium and most of the participants’
expertise. However, it was noted that there is an
existing ﬁeld on currently used claims forms for
subcodes or modiﬁers of National Drug Codes. The
Medicare Payment Advisory Commission (MedPAC)
in comments to the CMS proposed rule for payment
of biosimilars under Medicare Part B stated that the
proposal would foster price competition and reduce
government expenditures.31 The Congressional
Budget Ofﬁce earlier reached the same conclusion.32
While the work group supported the principle of
lower prices to the health care system in general, as
well as lower beneﬁciary prices (as a result of lower
coinsurance), it did not want to compromise pharmacovigilance for incremental cost savings.
What If Any Postmarketing Surveillance Studies
Should Be Required?
On March 6, 2015, the FDA approved ﬁlgrastimsndz (Zarxio Injection, Sandoz) as a biosimilar to
ﬁlgrastim (US-licensed Neupogen, Amgen). The
FDA required no postmarketing studies. The work
group believed that biosimilars should require postmarketing surveillance. The speciﬁc studies should be
based on the safety proﬁle of the reference product.
The work group generally agreed that the initial
period of postmarketing surveillance period should be
in the range of 2 to 4 years, as adopted in Europe.
Should There Be Uniform Guidance for Health Plans
Regarding Payment Tiers?
The work group strongly believed that health plans
should be free to operate independently with respect
to payment for biosimilars.

EDUCATION OF PHYSICIANS AND DIRECT
PATIENT CARE PROVIDERS WORK GROUP REPORT
Physicians and advanced practice providers who
prescribe biosimilar agents should be offered education to deﬁne and clarify the differences between
small-molecule and generic products, large-molecule
biologic reference drugs, and biosimilars. When prescribers entertain the option of prescribing a biosimilar ESA, they must understand that a batch of
either epoetin alfa or darbepoetin alfa does not
constitute an absolutely homogeneous group of
molecules due to the inherent heterogeneity of
products produced by living cells, compounded by

manufacturing changes that occur over time. Only the
primary structure of the molecules is replicated
exactly, whereas the overall structure is not. Box 2
outlines the important educational concepts
regarding biosimilar agents. Because biosimilar
products will not be made by the manufacturer of the
reference product, the quality of the newer product
may be questioned. The track record of quality for
each manufacturer of biosimilar agents, in addition to
cost, will be of particular importance for decision
makers who determine which products are available
on their formulary. These complex molecules can be
challenging to produce, so clinicians need information
about the manufacturing process and any problems
encountered by the manufacturer, especially because
such issues have occurred in the past. With respect to
ESAs, biosimilars must acknowledge the possibility
of PRCA, just as the reference drugs do. When
feasible, risks should be quantitatively expressed. For
each biosimilar product, the dose and dosing strategies must be illustrated in comparison to the reference
molecule. Comparative data regarding efﬁcacy should
be reported. All potential severe adverse effects should
be made available to prescribers, even if they are the
same as the reference molecule. Any adverse effects
signiﬁcantly different or more severe than those
associated with the reference molecule should point to
a manufacturer-related “defect” and thus underscores
the importance of postmarketing surveillance.
Educational programs for patients will be important. Although several features of this program would
be similar to the program for physicians and advanced
practice providers (ie, deﬁnition of a biosimilar, efﬁcacy, and safety), additional considerations are
required (Box 3). If a clinician chooses to switch a
patient from a reference molecule product to a biosimilar, the reason for that switch should be made
clear to the patient. As with all patient education
programs, the patient’s ability to understand, process,
and recall complex medical information must be
considered, and educational tools should be created
for different levels of medical literacy.33-35 This is
particularly important for patients with end-stage
renal disease, who often have impaired cognitive
function, multisystem disease, and complex medical
and dialysis prescriptions. There is some evidence

Box 2. Important Educational Concepts Regarding
Biosimilar Agents







Concept of reference vs biosimilar molecule
Efficacy
Safety
Manufacturing process equivalency
Adverse serious event frequency
Agent-specific serious adverse effects
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Box 3. Educational Issues for Patients Regarding
Biosimilar Agents
Are there any specific advantages or disadvantages of
biosimilar agents when compared to the reference agent?
Are the known potential risks the same for the biosimilar
product as for the reference product?
Are there any possible additional risks?
How much clinical experience has there been for a
biosimilar compared to the reference molecule product?
How will the cost of the product figure into the decision for
the reference vs biosimilar product?







that engaging peers as mentors and teachers may
assist patients in managing their disease.36 Such
engagement is particularly important because patients
with CKD have low health literacy in general.37

BIOSIMILARS RESEARCH IN KIDNEY DISEASE
WORK GROUP REPORT
An important goal of complementary studies of
biosimilars in kidney disease is to examine the unmet
needs that might not be addressed by the trials or other
vetting for regulatory approval. Data need to be
collected and analyzed for a number of pertinent study
questions, including overcoming clinician and patient
uncertainty about the safety and efﬁcacy of biosimilars
and their interchangeability with the reference products. A fundamental question is how to examine the
interchangeability in the context of a regulatory
construct as opposed to distinct clinical implications
that might extend beyond regulatory requirements. A
relevant analogy is the use of different iron dextran
formulas in the United States under the same generic
designation. Beginning in 2008, the same Medicare
billing code has been used for different types of iron
dextran, an injectable iron product used for treatment
of iron depletion. The perceived interchangeability
across 2 distinct molecular weights of iron dextran,
namely lower (INFeD, Watson Pharma, Inc) versus
higher (Dexferrum, American Regent) molecularweight formulations, was questioned as a result of
different safety and adverse-event proﬁles reported in
observational studies conducted after those needed for
FDA approval of these agents.38 This historical
example demonstrates the importance of research to
identify pre- and postmarketing commonalities and
distinctions of individual agents that may (or may not)
eventually be considered interchangeable under a
unifying biosimilar designation.
Clinically relevant differences should be examined
for individual medication lots that may use the same
international nonproprietary name or identical
sufﬁx provision. To that end, data integrity is of high
importance in the postapproval phase of biosimilars
to enable research on multiple drug comparisons. Among potential factors that may inﬂate the
848

differences across so-called interchangeable agents is
the frequency of changes in biosimilar molecules over
a given period in a given patient population. Studies
are needed to examine putative risk factors that may
contribute to distinctions based on differential effects
at the individual patient level and among different
populations, for example, by age, sex, race, ethnicity,
comorbid conditions, CKD stage, and end-stage renal
disease duration. Another clinically relevant target for
immediate research is to examine effective approaches to optimize surveillance for and detection of
PRCA, which could be difﬁcult to identify given
typical cases with multiple exposures of different
ESAs. It should be noted that the cluster of PRCA
cases in Europe related to the interaction between the
stabilizing agent in the ESA and rubber in the preﬁlled syringes was not identiﬁed rapidly by pharmacovigilance and was primarily driven by the insights
of Dr Nicole Casadevall and her colleagues.26 To
ensure high-quality and reproducible research, wellthought-out standard operating procedures should be
designed and in place. These standard operating
procedures are essential for effective workup and
comprehensive data collection for the targeted
studies. Some of the examples of the needed steps and
tests may include, but are not limited to, measuring
reticulocytes and relevant antibodies and other serologic tests.
Given that there may appear to be little incentive
for pharmaceutical companies to pursue postapproval
trials of biosimilars, the dialysis industry should be
engaged proactively in discussions related to additional research on biosimilars. Concerted efforts are
needed to collect safety data from dialysis providers
and enhance the effectiveness of the postapproval
research in order to ensure the external validity of the
studies. Both large and small dialysis organizations
should be approached. Collaboration with large dialysis companies is of particular importance given that
about two-thirds of all maintenance dialysis patients
in the United States are currently under the care of 2
large dialysis organizations, Fresenius Medical Care
and DaVita Healthcare Partners. Legitimate motivations and potential risks and liabilities for the dialysis
organizations need to be effectively and comprehensively explored and transparently addressed in order
to encourage the dialysis providers to allow and
enhance design and conduct of these studies. As an
example, the “tracking and tracing” approaches can
be automated in the dialysis clinics and incorporated
in the standard operating procedures that can be
realigned with the dialysis treatment protocols and
procedures. The route of administration is an exceptionally relevant piece of information that needs to be
captured with high levels of granularity and accuracy.
Whereas there seems to be little worry about IV
Am J Kidney Dis. 2016;68(6):843-852
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administration of the biosimilar agents for anemia
management in CKD, a higher level of surveillance is
expected for subcutaneous administration of biosimilar ESAs given the historical background (higher
rates of PRCA with subcutaneous injections).39 In
addition to major adverse events, non–life-threatening
symptoms that are relevant to patients and providers
should be collected with greater detail.
Pragmatic trials with cluster randomization or
retrospective cohort trials can be designed with the
support of dialysis providers, similar to studies that
have been conducted to compare IV paricalcitol and
doxercalciferol administrations or IV versus oral
vitamin D analogues.40 Studies in healthy volunteers
have indicated that erythropoietin therapy has effects
on platelet reactivity,41,42 but the clinical signiﬁcance
in patients with CKD is unclear.43
In addition to surveillance data collection and
postmarketing registry research, research could
examine outcomes such as those listed in Box 4.
The mentioned proposed lines of research can also
serve to address the safety questions related to the use
of biosimilars in not only in-center hemodialysis
Box 4. Potential Areas for Outcomes Research With Biosimilar
Erythropoiesis-Stimulating Agents








“Hard” outcome measures
 Mortality
 Hospitalizations
 Chronic kidney disease progression rate
 Renal transplant survival
Intermediate outcome measures
 Thromboembolic events, including cerebrovascular
and cardiac events
 Dialysis vascular access events, including occlusion
and patency longevity
 Endothelial function tests
 Platelet indexes, including platelet counts, mean
platelet volume, platelet function tests, and other biomarkers such as p-selectin
 Blood pressure–related data, including peak and nadir
blood pressure values and changes in antihypertensive medications
 Carcinogenicity data
Efficacy data
 Frequency of blood transfusion
 Administered iron supplementations, including repletion (“load and hold”) vs maintenance therapy
 Hemoglobin levels and other indexes of iron and
anemia
 Prescribed dose of the drug
Patient-reported outcome measures
 Health-related quality of life
 Clarity of the information conveyed and accuracy
of the perception of patients about switching between
reference agents and biosimilars
 Patients’ opinions, thoughts, and beliefs pertaining to
the use of biosimilars, including the views of vulnerable patients with regard to potentially hidden therapy
switches and putative subterfuge

patients, but also in home dialysis and non2dialysisdependent patients with CKD, who are more likely to
receive subcutaneous injections of these agents. To
that end, national Medicare and Veterans Administration databases can be examined, in which such
granular data can be better tracked for complementary research given that trials that are performed for
FDA approval might not have captured certain levels
of potential adverse events or rare patient symptoms
in the “needle-in-a-haystack” areas. More thought
and consensus building meetings and discussions
may be needed pertaining to efﬁcacy metrics, dose
response, transfusion indications, packaging for low
versus high doses, billing code (J-code), and nature
of adverse reactions that may not be required by the
FDA but that can be clinically relevant to both patients and physicians. Potential measures for efﬁcacy
research include but are not limited to those listed
in Box 4.
It may be argued that who beneﬁts economically
versus clinically from the use of biosimilars may not
be a scientiﬁc research question; however, careful
investigation of the ﬁnancial aspects of biosimilars in
the context of safety and efﬁcacy research can expand
the scope of relevant study questions considerably. It
is far from clear whether the lower costs of biosimilar
ESAs would prompt a newer look at relatively costly
iron products and how such emerging scenarios can
effectively be studied. Dialysis providers may choose
to use a biosimilar ESA and direct the savings to
enhance patient care and support research for patient
beneﬁt. In addition, broader level beneﬁts may be
examined, for instance, whether society at large and
taxpayers value a slower rate of increase in health care
costs as a result of biosimilar use.
In conclusion, reliable individual agent identiﬁcation is essential for effective surveillance and related
postapproval research on biosimilars. Expanded
pharmacovigilance beyond the FDA-mandated levels
is needed to ensure that investigators can more
effectively develop and choose from among highpriority research questions for the safety and efﬁcacy of biosimilars. Additional adverse events in
addition to traditionally known conditions such as
PRCA, including anaphylaxis, should be examined.
Although it is highly unlikely that biosimilar ESAs
will show a difference from originator ESAs due to
the preapproval vetting that requires the former to be
highly similar to the latter with no clinically meaningful differences in safety, purity, and potency,
postmarketing research may explore areas such as
thromboembolic events, platelet markers, hypertension research, dose-response phenomenon, iron indexes, hard outcomes, and patient-reported outcomes
using larger patient cohorts and longer durations of
exposure that exceed the statistical power of phase 3
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studies. Finally, cost-effectiveness analyses in the real
world will be welcome to demonstrate that biosimilar
products have achieved their goal of reducing health
care expenditures while increasing patient access to
valuable therapeutic agents.

SUMMARY
In developing and ﬁnalizing its guidance for
approval of biosimilar agents, the FDA has drawn
upon its experience in evaluating the results of
manufacturing process changes by the sponsors of
reference biologics that may result in small physiochemical or bioactivity changes in the product, its
experience in evaluating biosimilar products that have
been in the registration pipeline since the pathway
was legislated by Congress in 2010, and the extensive
European experience with biosimilar evaluation,
approval, and pharmacovigilance since 2007.
Congress legislated the approval pathway for biosimilars to bring these lower cost products to market
in a timely and efﬁcient manner to decrease overall
health care costs and increase patient access while
protecting patient safety. As of the end of 2015, only
one agent, ﬁlgrastim-sndz, a granulocyte colonystimulating factor, had been approved via this
pathway in the United States. In April 2016, the FDA
approved inﬂiximab-dyyb (Inﬂectra, Pﬁzer), a biosimilar of inﬂiximab (Remicade, Janssen). The
approval of Hospira/Pﬁzer’s biosimilar epoetin was
anticipated in November 2015, but the application
was returned to the sponsor by the FDA with a
request for additional information. The uptake of
biosimilar ESAs in Europe has varied among countries and relates mostly to the price differential between the biosimilar agents and the reference agents.
Overall, biosimilar ESAs had about one-third of
market share for all ESAs in Europe as of 2014.44
When biosimilar ESAs are approved in the United
States, decisions regarding their use will be a function
of cost savings versus residual safety concerns. In the
environment of end-stage renal disease, because biosimilar ESAs will be included in the bundled payment, cost savings will initially accrue to the dialysis
provider but will likely be eventually reclaimed by the
CMS in another round of rebasing the bundled payment.45 It is likely that health plans and dialysis
providers will encourage the use of biosimilar ESAs
by requiring less hassle and paperwork to prescribe
them versus the reference agent, so interchangeability
becomes less of a driver to the use of biosimilar
agents than formulary decisions. If a biosimilar ESA
is deemed interchangeable, the process for substitution at the pharmacy level will vary according to state
law, but all states will allow the prescriber to prevent
substitution by writing “DAW” or words to that effect. If substitution occurs, it will be vital for both the
850

prescriber and patient to be informed so that any
adverse reactions can be attributed to a speciﬁc agent.
Pharmacovigilance to identify patterns and trends of
adverse events will require unique identiﬁers for each
agent.
Biosimilars are a new frontier of therapy in the
United States and constitute a learning, research, and
public policy opportunity for all stakeholders. Despite
the current global use of biosimilars, there remains a
lack of data. The expansion of biosimilar ESAs into
the US market should answer many questions
regarding their efﬁcacy, safety, and pharmacoeconomics at a level of statistical power not previously
achieved. In order for this occur, the appropriate
educational, investigative, and policy (at the state and
federal level) infrastructure must be in place as these
agents are approved. As a principal stakeholder and
patient advocate, the nephrology profession will be
looked to for leadership in this process.
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